Serum Institute CEO informs Home Minister Amit Shah about COVID-19 vaccine rollout

Published On 2021-02-28 05:00 GMT   |   Update On 2021-02-28 05:01 GMT

New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Friday said he met Union Home Minister Amit Shah and apprised him about the ongoing COVID-19 vaccine rollout in the country."It was my honour to brief you today, Shri Hon''ble @AmitShah Ji on the vaccine capabilities of our country and the ongoing rollout of vaccines in India," Poonawalla said in a tweet.In January, the...

Login or Register to read the full article

New Delhi: Serum Institute of India (SII) CEO Adar Poonawalla on Friday said he met Union Home Minister Amit Shah and apprised him about the ongoing COVID-19 vaccine rollout in the country.

"It was my honour to brief you today, Shri Hon''ble @AmitShah Ji on the vaccine capabilities of our country and the ongoing rollout of vaccines in India," Poonawalla said in a tweet.

In January, the country''s drugs regulator had approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.

Read also: Prioritising domestic vaccine needs, asks for patience: Serum Institute of India

Apart from making efforts to meet the requirements of India, SII, the world''s largest vaccine maker, is also trying its best to balance the needs of the rest of the world.


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News